{"id":"insulin-asparte","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin aspart is a genetically engineered insulin analog with a single amino acid substitution (proline to aspartic acid at position 28 of the B chain) that reduces self-association and enables faster absorption from subcutaneous injection sites compared to human insulin. It mimics the body's natural rapid postprandial insulin secretion by quickly lowering blood glucose levels through enhanced cellular glucose uptake and suppression of hepatic glucose production.","oneSentence":"Insulin aspart is a rapid-acting insulin analog that binds to insulin receptors on cells to promote glucose uptake and utilization.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:21.151Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT02556840","phase":"NA","title":"Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-04-25","conditions":"Maturity-Onset Diabetes of the Young","enrollment":46},{"nctId":"NCT04012138","phase":"PHASE4","title":"Insulin Dextrose Infusion vs Nebulized Salbutamol vs Combination of Salbutamol and Insulin Dextrose in Acute Hyperkalemia","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2019-12-20","conditions":"Hyperkalemia","enrollment":525},{"nctId":"NCT00072904","phase":"PHASE3","title":"Diabetes Therapy to Improve BMI and Lung Function in CF","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2001-06","conditions":"Cystic Fibrosis, Diabetes Mellitus","enrollment":108}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ABNORMAL BEHAVIOUR"},{"count":1,"reaction":"ACCIDENTAL EXPOSURE TO PRODUCT"},{"count":1,"reaction":"ACUTE KIDNEY INJURY"},{"count":1,"reaction":"AGGRESSION"},{"count":1,"reaction":"AMNESIA"},{"count":1,"reaction":"ANAL ATRESIA"},{"count":1,"reaction":"ATRIAL SEPTAL DEFECT"},{"count":1,"reaction":"BLADDER AGENESIS"},{"count":1,"reaction":"BLOOD GLUCOSE DECREASED"},{"count":1,"reaction":"BLOOD GLUCOSE FLUCTUATION"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Insulin Asparte","genericName":"Insulin Asparte","companyName":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","companyId":"national-institute-of-diabetes-and-digestive-and-kidney-diseases-niddk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin aspart is a rapid-acting insulin analog that binds to insulin receptors on cells to promote glucose uptake and utilization. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}